DPP4 and type 2 diabetes mellitus: Incretin-based therapies such as DPP-4 inhibitors have demonstrated the ability to potentiate GABAergic, dopaminergic, serotonergic, and noradrenergic neurotransmission, which are crucial pathways for awakening drugs in both coma and prolonged DOC (see Introduction).